Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus best supportive care versus placebo plus best supportive care in previously treated metastatic colorectal cancer
NL-OMON34893Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) and colon cancer comparing Regorafenib plus BSC with Placebo plus BSC (2 arms). Primary endpoint: Overall survival. Started Nov 2010; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)colon cancer
Beyond the preview
Go deeper on NL-OMON34893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34893.